Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag ADR (OP:BAYRY)

10.97 -0.23 (-2.05%)
Streaming Delayed Price Updated: 3:32 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bayer Ag ADR

< Previous 1 2 Next >
News headline image
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
From Bayer
Via Business Wire
News headline image
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
From Bayer
Via Business Wire
News headline image
Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
From Bayer
Via Business Wire
News headline image
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
From Bayer
Via Business Wire
News headline image
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
From Bayer
Via Business Wire
News headline image
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign
From Bayer
Via Business Wire
News headline image
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
From Bayer
Via Business Wire
News headline image
Bayer Accelerates Pharma Growth on High-Value Portfolio
From Bayer
Via Business Wire
News headline image
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus
From Bayer
Via Business Wire
News headline image
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
From Bayer
Via Business Wire
News headline image
Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference
From Bayer
Via Business Wire
News headline image
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
From Bayer
Via Business Wire
News headline image
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
From Bayer
Via Business Wire
News headline image
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
From Bayer
Via Business Wire
News headline image
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
From Bayer
Via Business Wire
News headline image
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
From Bayer
Via Business Wire
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
From Bayer
Via Business Wire
News headline image
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
From Bayer
Via Business Wire
News headline image
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
From Bayer
Via Business Wire
News headline image
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
From Bayer
Via Business Wire
News headline image
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
From Bayer
Via Business Wire
News headline image
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
From Bayer
Via Business Wire
News headline image
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
From Bayer
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.